Magnetic Resonance Imaging Guided Gynecologic Brachytherapy

Status Completed

Clinical Trial Summary

The primary goal of this pilot study is to assess the feasibility of using magnetic resonance (MR) imaging guidance in the Magnetic Resonance Therapy (MRT) unit at the Brigham and Women's Hospital during the implantation of brachytherapy applicators in patients with gynecologic malignancies. Patients with gynecologic malignancies requiring brachytherapy are currently treated under either fluoroscopic or CT visualization of the brachytherapy applicator. Magnetic resonance imaging has been shown in many studies to provide superior visualization of the cervix, vagina and uterus compared to CT. However no prior study has examined the feasibility of using real-time magnetic resonance imaging to assist in the guidance of gynecologic brachytherapy applicators

Clinical Trial Description

The primary endpoint involves the ability of the MRT guided procedure to protect bladder and rectal tissues from inadvertent insertion of the interstitial needles used to deliver brachytherapy. MR images obtained on the MRT unit should provide clear delineation of the bladder and rectum and allow for greater accuracy and avoidance of these normal tissues upon interstitial needle insertion. CT images will be obtained following the insertion of needles using the MRT unit. The procedure will be considered a failure if CT imaging identifies the insertion of needles into the bladder or rectum that was not detected using MR. Secondary endpoints include the ability of MR imaging to accurately reconstruct dosimetric plans and to construct dose volume histograms after the implantation of interstitial needles as well as the ability of MR imaging to accurately determine tumor, bladder and rectal volumes. Secondary endpoints will also include the assessment of acute skin, genitourinary and gastrointestinal toxicities as well as an assessment of tumor progression or recurrence during a 180 day follow-up period. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00112307
Study type	Interventional
Source	Brigham and Women's Hospital
Contact
Status	Completed
Phase	N/A
Start date	March 2003
Completion date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02374411` - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients	N/A
Completed	`NCT00377520` - A Trial for Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT04063072` - ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.	N/A
Terminated	`NCT01969396` - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology	N/A
Terminated	`NCT00669422` - ChemoFx® PRO - A Post-Market Data Collection Study	N/A
Recruiting	`NCT01564264` - Sentinel Node Biopsy in Endometrial Cancer	N/A
Completed	`NCT00231855` - Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers	Phase 2
Completed	`NCT04679675` - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial	N/A
Completed	`NCT04351139` - Impact of the COVID-19 Pandemic in Gynecological Oncology
Completed	`NCT05004623` - Early Feasibility Study of the "Easy Light" Fluorecence Imaging System	N/A
Completed	`NCT02454036` - Biobehavioral Intervention in Gynecologic Oncology Patients	Phase 2
Completed	`NCT00188578` - Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)	Phase 1/Phase 2
Active, not recruiting	`NCT03951415` - Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer	Phase 2
Completed	`NCT01654458` - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer	N/A
Completed	`NCT00190918` - A Trial for Patients With Gestational Trophoblastic Disease	Phase 2
Completed	`NCT00050440` - Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma	Phase 2
Completed	`NCT00250783` - Pre-Clinical Models in Gynecological Tumors A Tissue Repository
Recruiting	`NCT03624712` - Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms
Completed	`NCT00628901` - A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)	Phase 4
Completed	`NCT00090389` - Acupuncture for Women's Health Conditions	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.